Integrating DNA Methylation and MicroRNA Biomarkers in Sputum for Lung Cancer Detection

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2016 Oct 26

PMID 27777637

Citations 42

Authors

Yun Su

Hongbin Fang

Feng Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Abnormal microRNA (miRNA) expressions and promoter methylation of genes detected in sputum may provide biomarkers for non-small lung cancer (NSCLC). Here, we evaluate the individual and combined analysis of the two classes of sputum molecular biomarkers for NSCLC detection.

Results: We analyze expression of 3 miRNAs (miR-21, miR-31, and miR-210) and methylation of 3 genes (, , and ), which were previously identified as potential biomarkers for NSCLC, in sputum of a set of 117 stage I NSCLC patients and 174 cancer-free smokers. The results are validated in a different set of 144 stage I NSCLC patients and 171 controls. The panel of 3 miRNA biomarkers has 81.5 % sensitivity and 85.9 % specificity; the panel of 3 methylation biomarkers displays 82.9 % sensitivity and 76.4 % specificity for NSCLC detection. Integrated analysis of 2 miRNAs (miR-31 and miR-210) and 2 genes ( and ) yields higher sensitivity (87.3 %) and specificity (90.3 %) compared with the individual panels of the biomarkers ( < 0.05). Combined analysis of all the 3 miRNAs and 3 genes does not have performance superior to that of the panel of 2 miRNAs and 2 genes ( > 0.05). The performance of combined use of the two classes of biomarkers was confirmed in the validation set.

Conclusions: The integration of two different classes of biomarkers synergistically improves both the sensitivity and the specificity for the early detection of NSCLC.

Citing Articles

Promoter Methylation as a Biomarker for Metastatic Risk in a Cohort of Non-Small Cell Lung Cancer Patients.

Thanou E, Lontra D, Balgouranidou I, Efthimiadou E, Delipetrou A, Tsaroucha E Biomolecules. 2025; 14(12.

PMID: 39766220 PMC: 11673096. DOI: 10.3390/biom14121514.

Improving CT scan for lung cancer diagnosis with an integromic signature.

Liao J, Dhilipkannah P, Jiang F J Biol Methods. 2024; 11(3):e99010023.

PMID: 39544186 PMC: 11557295. DOI: 10.14440/jbm.2024.0028.

The role of DNA methylation and DNA methyltransferases (DNMTs) as potential biomarker and therapeutic target in non-small cell lung cancer (NSCLC).

Mohd Kamal K, Ghazali A, Ab Mutalib N, Abu N, Chua E, Masre S Heliyon. 2024; 10(19):e38663.

PMID: 39403460 PMC: 11472108. DOI: 10.1016/j.heliyon.2024.e38663.

Multisite DNA methylation alterations of peripheral blood mononuclear cells serve as novel biomarkers for the diagnosis of AIS/stage I lung adenocarcinoma: a multicenter cohort study.

Li P, Liu S, Wang T, Wang F, Li J, Qi Q Int J Surg. 2024; 111(1):40-54.

PMID: 39352118 PMC: 11745624. DOI: 10.1097/JS9.0000000000002101.

Integrated analysis of the role of PR/SET domain 14 in gastric cancer.

Li X, Wang C, Wang Y, Chen X, Li Z, Wang J BMC Cancer. 2024; 24(1):685.

PMID: 38840106 PMC: 11151633. DOI: 10.1186/s12885-024-12424-1.

References

Su J, Liao J, Gao L, Shen J, Guarnera M, Zhan M . Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis. Oncotarget. 2015; 7(5):5131-42. PMC: 4868676. DOI: 10.18632/oncotarget.4219. View

Liu J, Shworak N, Sinay P, Schwartz J, Zhang L, Fritze L . Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem. 1999; 274(8):5185-92. DOI: 10.1074/jbc.274.8.5185. View

Li R, Todd N, Qiu Q, Fan T, Zhao R, Rodgers W . Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res. 2007; 13(2 Pt 1):482-7. DOI: 10.1158/1078-0432.CCR-06-1593. View

Donninger H, Vos M, Clark G . The RASSF1A tumor suppressor. J Cell Sci. 2007; 120(Pt 18):3163-72. DOI: 10.1242/jcs.010389. View

Jiang F, Todd N, Li R, Zhang H, Fang H, Stass S . A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila). 2010; 3(12):1571-8. DOI: 10.1158/1940-6207.CAPR-10-0128. View

Wang S, Hu J, Zhang D, Li J, Fei Q, Sun Y . Prognostic role of microRNA-31 in various cancers: a meta-analysis. Tumour Biol. 2014; 35(11):11639-45. DOI: 10.1007/s13277-014-2492-x. View

Chang W, Lee C, Park J, Park M, Maeng L, Yoon C . Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci. 2013; 14(1):69-76. PMC: 3615234. DOI: 10.4142/jvs.2013.14.1.69. View

Chen H, Zhang C, Sheng Y, Yao S, Liu Z, Zhang C . Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma. Am J Cancer Res. 2015; 5(1):180-90. PMC: 4300694. View

Hubers A, van der Drift M, Prinsen C, Witte B, Wang Y, Shivapurkar N . Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer. 2014; 84(2):127-33. DOI: 10.1016/j.lungcan.2014.01.019. View

10.

Hesson L, Cooper W, Latif F . Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007; 26(52):7283-301. DOI: 10.1038/sj.onc.1210547. View

11.

Jiang F, Yin Z, Caraway N, Li R, Katz R . Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia. 2004; 6(5):623-35. PMC: 1531667. DOI: 10.1593/neo.04142. View

12.

Xie Y, Todd N, Liu Z, Zhan M, Fang H, Peng H . Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2009; 67(2):170-6. PMC: 2846426. DOI: 10.1016/j.lungcan.2009.04.004. View

13.

Belinsky S, Nikula K, Palmisano W, Michels R, Saccomanno G, Gabrielson E . Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998; 95(20):11891-6. PMC: 21736. DOI: 10.1073/pnas.95.20.11891. View

14.

Hubers A, Brinkman P, Boksem R, Rhodius R, Witte B, Zwinderman A . Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. J Clin Pathol. 2014; 67(8):707-11. DOI: 10.1136/jclinpath-2014-202414. View

15.

Leonhardt H, Cardoso M . DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl. 2001; Suppl 35:78-83. DOI: 10.1002/1097-4644(2000)79:35+<78::aid-jcb1129>3.0.co;2-j. View

16.

Qiu Q, Todd N, Li R, Peng H, Liu Z, Yfantis H . Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer. 2008; 114(4):275-83. PMC: 4255556. DOI: 10.1002/cncr.23596. View

17.

Saccomanno G, Saunders R, Archer V, AUERBACH O, Kuschner M, BECKLER P . Cancer of the lung: the cytology of sputum prior to the development of carcinoma. Acta Cytol. 1965; 9(6):413-23. View

18.

Li R, Wang H, Bekele B, Yin Z, Caraway N, Katz R . Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene. 2005; 25(18):2628-35. DOI: 10.1038/sj.onc.1209289. View

19.

Lawrie C, Gal S, Dunlop H, Pushkaran B, Liggins A, Pulford K . Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5):672-5. DOI: 10.1111/j.1365-2141.2008.07077.x. View

20.

Hubers A, Heideman D, Burgers S, Herder G, Sterk P, Rhodius R . DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. Br J Cancer. 2015; 112(6):1105-13. PMC: 4366885. DOI: 10.1038/bjc.2014.636. View